Reid Huber
About Reid Huber
Reid Huber is a Director at Synnovation Therapeutics and has held several leadership roles in the biotechnology sector, including positions at Rapport Therapeutics and Third Rock Ventures. He has a strong academic background with a PhD in Molecular Genetics/Biochemistry and extensive experience in scientific research and company formation.
Work at Synnovation Therapeutics
Reid Huber serves as the Director at Synnovation Therapeutics, a role he has held since 2023. Located in Wilmington, Delaware, he has been contributing to the company's strategic direction and scientific initiatives for one year.
Previous Experience at Rapport Therapeutics
Prior to his current role, Reid Huber was the CEO of Rapport Therapeutics for a brief period of three months in 2022. He also holds the position of Director at Rapport Therapeutics, where he has been working since 2022 in Boston, Massachusetts.
Background in Scientific Research
Reid Huber has a solid foundation in scientific research, having worked at DuPont and Bristol-Myers Squibb from 1998 to 2002. His extensive experience in the pharmaceutical industry includes leadership roles that have shaped research directions and strategic initiatives.
Education and Expertise
Reid Huber earned a Bachelor of Science degree in Molecular Genetics and Biochemistry from Murray State University, where he studied from 1991 to 1994. He further advanced his education by obtaining a PhD in Molecular Genetics and Biochemistry from Washington University School of Medicine in St. Louis, completing his studies from 1994 to 1998.
Achievements at Third Rock Ventures
Since joining Third Rock Ventures in 2018 as a Partner, Reid Huber has played a significant role in the formation and strategic development of the firm's portfolio companies. His contributions have been instrumental in guiding the direction of various biotechnology initiatives.